Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Short term Debt (2024 - 2026)

Adaptin Bio's (APTN) quarterly Short term Debt came in at $162208.0 in Q2 2026, down 32.61% quarter-over-quarter from $240698.0 in Q1 2026.

Analysis

Adaptin Bio (APTN) Short term Debt (2024 - 2026) Analysis & Trends

Adaptin Bio has disclosed Short term Debt across 2 years of filings, most recently posting $162208.0 for Q2 2026.

  • In Q2 2026, Short term Debt changed N/A year-over-year to $162208.0; the TTM figure through Jun 2026 stood at $162208.0 (changed N/A YoY), while the FY2024 annual figure was $1.2 million, changed N/A from the prior year.
  • Short term Debt came in at $162208.0 for Q2 2026 at Adaptin Bio, down from $240698.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.2 million in Q4 2024 to a low of $162208.0 in Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn
10 Adaptin Bio 56.76 Mn 56.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 162,208.00
Mar 31, 2026 240,698.00
Dec 31, 2024 1.25 Mn